Suven Life Sciences' Q1 FY 2025-26 Quarterly Results

Result Summary

• Suven Life Sciences Ltd reported a 63.0% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 50.7%.
• Its expenses for the quarter were up by 57.8% QoQ and 63.4% YoY.
• The net profit increased 94.1% QoQ and increased 83.7% YoY.
• The earnings per share (EPS) of Suven Life Sciences Ltd declined at 2.4 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Suven Life Sciences Ltd is a biopharmaceutical company that primarily focuses on the discovery and development of new chemical entities (NCEs) for central nervous system disorders. The company operates within the pharmaceutical industry, specifically targeting therapeutic areas such as Alzheimer's, schizophrenia, depression, and other cognitive disorders. As of the latest information, Suven Life Sciences has been involved in advancing its pipeline of NCEs through various phases of clinical trials. The company is also engaged in contract research and manufacturing services, which contribute to its business operations. Any recent major developments specific to Suven Life Sciences beyond the scope of the provided data are not available.

Revenue

In Q1FY26, Suven Life Sciences Ltd reported a total income of ₹2.47 crores, compared to ₹6.67 crores in Q4FY25 and ₹5.01 crores in Q1FY25. This represents a quarter-over-quarter (QoQ) decline of 63.0% and a year-over-year (YoY) decrease of 50.7%. The significant reduction in total income over both periods may reflect fluctuations in the company's revenue from its core operations, including contract manufacturing or sales of NCEs. The data does not provide specific insights into the causes behind these changes.

Profitability

The financial data indicates that Suven Life Sciences Ltd faced a challenging quarter in terms of profitability. The company recorded a profit before tax (PBT) of -₹51.52 crores in Q1FY26, which reflects a deterioration from -₹27.54 crores in Q4FY25 and -₹28.04 crores in Q1FY25. The increase in losses is evident with a QoQ change of 87.1% and a YoY change of 83.7%. Tax expenses were reported as zero in Q1FY26, compared to a tax credit of -₹1.00 crore in Q4FY25. Consequently, the profit after tax (PAT) also mirrored the PBT figures, showing a QoQ increase in losses by 94.1% and a YoY increase by 83.7%. Earnings per share (EPS) declined to -₹2.40 in Q1FY26 from -₹1.20 in Q4FY25 and -₹1.30 in Q1FY25, representing a QoQ change of 100.0% and a YoY change of 84.6%.

Operating Metrics

Suven Life Sciences Ltd's operating performance for Q1FY26 indicates heightened expenses with total expenses reported at ₹53.99 crores. This marks a significant rise from ₹34.21 crores in Q4FY25 and ₹33.05 crores in Q1FY25, resulting in a QoQ increase of 57.8% and a YoY increase of 63.4%. The increase in expenses amidst declining revenues suggests a challenging operational environment. These operating metrics underscore the financial struggles faced by the company during the quarter, impacting its bottom line significantly. The data provided does not elaborate on specific areas where expenses increased or the reasons behind these cost escalations.